Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling

Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting

(2020) Rona Yaeger et al.   CLINICAL CANCER RESEARCH

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition

(2020) Jenny Y. Xue et al.   NATURE

T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity

(2020) Marta Canel et al.   eLife

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer

(2020) Jay B. Fell et al.   JOURNAL OF MEDICINAL CHEMISTRY

SynergyFinder 2.0: visual analytics of multi-drug combination synergies

(2020) Aleksandr Ianevski et al.   NUCLEIC ACIDS RESEARCH

EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer

(2020) Vito Amodio et al.   Cancer Discovery

Current therapy of KRAS-mutant lung cancer

(2020) Aron Ghimessy et al.   CANCER AND METASTASIS REVIEWS

Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer

(2020) Yuta Adachi et al.   CLINICAL CANCER RESEARCH

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

(2020) David S. Hong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice

(2020) Sarah Alsamman et al.   Science Translational Medicine

Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma

(2019) Yanxia Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK

(2019) Xiaodong Feng et al.   CANCER CELL

Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion

(2019) Hong Jiang et al.   GUT

Direct Ras G12C inhibitors: crossing the rubicon

(2019) Colin R. Lindsay et al.   BRITISH JOURNAL OF CANCER

Drugging an undruggable pocket on KRAS

(2019) Dirk Kessler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells

(2019) Giulia Gobbi et al.   ONCOGENE

FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy

(2019) Carlos J Diaz Osterman et al.   eLife

Epigenetic SMAD3 repression in tumor-associated fibroblasts impairs fibrosis and response to the antifibrotic drug nintedanib in lung squamous cell carcinoma

(2019) Rafael Ikemori et al.   CANCER RESEARCH

YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling

(2019) Grace E. Coggins et al.   CANCER RESEARCH

Vertical pathway inhibition overcomes adaptive feedback resistance to KRASG12C inhibition

(2019) Meagan B. Ryan et al.   CLINICAL CANCER RESEARCH

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

Statistical determination of synergy based on Bliss definition of drugs independence

(2019) Eugene Demidenko et al.   PLoS One

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

(2019) Jill Hallin et al.   Cancer Discovery

Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors

(2019) Brian A. Lanman et al.   JOURNAL OF MEDICINAL CHEMISTRY

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer

(2019) David E. Gerber et al.   LUNG CANCER

The Cancer Genome Atlas: Creating Lasting Value beyond Its Data

(2018) Carolyn Hutter et al.   CELL

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

(2018) Matthew R. Janes et al.   CELL

FAK controls the mechanical activation of YAP, a transcriptional regulator required for durotaxis

(2018) Dariusz Lachowski et al.   FASEB JOURNAL

Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype

(2018) Ulrich A. Hirt et al.   Oncogenesis

The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer

(2018) Stefanie Tiede et al.   Oncogenesis

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

(2018) Sandra Misale et al.   CLINICAL CANCER RESEARCH

FAK inhibitors in Cancer, a patent review

(2017) Peng-Cheng Lv et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance

(2017) Cecilia S. Leung et al.   JOURNAL OF CLINICAL INVESTIGATION

Hippo pathway mediates resistance to cytotoxic drugs

(2017) Taranjit S. Gujral et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

AACR Project GENIE: Powering Precision Medicine through an International Consortium

(2017)   Cancer Discovery

YAP/TAZ at the Roots of Cancer

(2016) Francesca Zanconato et al.   CANCER CELL

miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3

(2016) Ying Zhou et al.   CANCER RESEARCH

Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer

(2016) K.-J. Tang et al.   CLINICAL CANCER RESEARCH

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

(2016) Hong Jiang et al.   NATURE MEDICINE

Heatmapper: web-enabled heat mapping for all

(2016) Sasha Babicki et al.   NUCLEIC ACIDS RESEARCH

Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling

(2016) P-F Zhang et al.   Cell Death & Disease

LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response

(2015) Fuming Li et al.   CANCER CELL

FAK to the Rescue: Activated Stroma Promotes a “Safe Haven” for BRAF-Mutant Melanoma Cells by Inducing FAK Signaling

(2015) Margaret C. Frame et al.   CANCER CELL

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

(2015) Eishu Hirata et al.   CANCER CELL

Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity

(2015) Alan Serrels et al.   CELL

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

(2015) Luping Lin et al.   NATURE GENETICS

KRAS and YAP1 Converge to Regulate EMT and Tumor Survival

(2014) Diane D. Shao et al.   CELL

RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas

(2013) Georgia Konstantinidou et al.   Cancer Discovery

Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks

(2012) Cole Trapnell et al.   Nature Protocols

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF -TRCP

(2010) B. Zhao et al.   GENES & DEVELOPMENT

TopHat: discovering splice junctions with RNA-Seq

(2009) Cole Trapnell et al.   BIOINFORMATICS

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

(2009) Da Wei Huang et al.   Nature Protocols